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lymphocyte proliferation of spleen cells, which all demon-
strate the enhancement of cell-mediated immunity, sug-
gested the phages could be a potent gene delivery system 
in animal models.  Conclusion: Our results suggest the re-
combinant phages can be used as effective biological tools 
for inducing E7-specific protective immune responses. 
Hence, the study introduces a possible therapeutic strategy 
against cervical cancer and other HPV-related neoplasia. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Human papillomaviruses (HPV) have been identified 
as the etiological agent of cervical carcinomas, the second 
most common malignancy in women worldwide  [1] . 
HPV are suspected to be also involved in the induction of 
other tumors. Hence, the development of prophylactic 
and therapeutic vaccines against HPV is of the utmost 
priority  [2] . Since the regression of lesions in HPV16-in-
fected humans appears to be associated with T helper cell 
(Th)1 and CD8+ T cell responses to the early proteins (es-
pecially E7 protein), an efficient therapeutic vaccination 
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 Abstract 
 Objective: Human papillomavirus (HPV) oncoproteins (i.e. 
E6 and E7) are constitutively expressed in cervical cancer 
cells. The proteins are ideal targets to be used for developing 
therapeutic vaccines against existing HPV-associated carci-
nomas. To date, whole bacteriophage (‘phage’)-  particles, 
rather than purified ‘naked’ DNA, have been described as 
highly efficient delivery vehicles for a DNA vaccine.  Meth-
ods: In this study, a safe and efficient   -based therapeutic 
cancer vaccine, recombinant   -ZAP E7 phage, was devel-
oped by inserting a HPV16 E7 gene into the Lambda ZAP  
cytomegalovirus vector.   -ZAP E7 phages were employed to 
immunize mice against the E7-expressing murine tumor cell 
line (TC-1), which is used as a tumor model in an H-2b murine 
system.  Results: The tumor-bearing mice indicated a signif-
icant inhibition of tumor growth after 3 injections of 2  ! 10 12 
particles of recombinant phages. Released lactate dehydro-
genase, interferon-  and granzyme B from spleen cells and 
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against HPV-associated disease will most likely depend 
on the induction of specific cellular immune responses 
 [3] . Therefore, HPV E7 is an ideal target antigen for de-
veloping therapeutic vaccines against HPV-associated 
neoplasms  [4] .
 Nucleic acid vaccines potentially have a number of ad-
vantages over traditional, attenuated, killed or subunit 
vaccines. They are cheaper and easier to produce than re-
combinant protein vaccines. The vaccines have fewer ad-
verse side effects, and they induce both cellular (Th1) and 
humoral (Th2) arms of the immune system. Studies in 
mice have demonstrated good antibody and cellular re-
sponses with nucleic acid vaccines  [5] . However, in some 
examples of protection against some diseases, trials in 
larger animals, humans and nonhuman primates have 
been plagued by a lack of efficacy when using naked DNA 
 [6] . Various methods have been tested to improve respons-
es to DNA vaccines, and they have been reviewed  [7] . 
However, many of these methods increase the cost or re-
duce the ease of production of DNA vaccines significantly, 
while others can present regulatory hurdles, and alterna-
tive ways to improve responses are still being sought.
 Whole phage nanoparticles are novel systems for gene 
delivery to animal cells  [8] . In this strategy, the gene en-
coding the vaccine antigen, under control of a suitable 
eukaryotic promoter, is incorporated into the phage ge-
nome. Subsequently, the phage particle is used to immu-
nize the host. 
 Bacteriophage vectors offer many advantages as vac-
cine delivery and transfer vectors due to their genetic 
tractability, inexpensive production, suitability for large-
scale production as well as their physical stability and 
compatibility with simple storage and formulation meth-
ods such as desiccation  [9, 10] . Bacteriophage-  offers 
many additional advantages as a DNA vaccine delivery 
system. Apart from being highly stable, the DNA is con-
tained within a protective protein matrix and is therefore 
not susceptible to nuclease degradation. Phage particles 
are targeted directly to antigen-presenting (AP) cells  [11, 
12] , which appears to result in much better immune re-
sponses than equivalent plasmid constructs at much low-
er doses  [8] .
 To date, a few researches have focused on the use of the 
well-characterized cloning vector phage-  as a gene de-
livery vehicle  [13] . The previous studies have demonstrat-
ed the expression cassettes containing the gene of interest 
under the control of cytomegalovirus (CMV) promoter 
using   -gt11 as a standard   -DNA cloning vector. Sig-
nificant immune responses have been presented using a 
variety of different vaccine expression cassettes  [8, 12] .
 In the present study, a Lambda ZAP  CMV DNA 
cloning vector has been employed to provide a bacterio-
phage particle formulation as a pharmaceutically accept-
able carrier. It has been shown that recombinant   -ZAP 
E7 phage induces therapeutic immunity against TC-1 tu-
mors in mice.
 Materials and Methods 
 Construction of   -Vaccines 
 A lambda ZAP CMV vector (Stratagene, USA) was used for 
the construction of recombinant   -bacteriophages. The vector 
has potential characteristics for expression in eukaryotic cells. 
Eukaryotic expression of inserts is driven by the CMV immedi-
ate-early promoter with the SV40 transcription terminator and 
polyadenylation signal. The   -ZAP E7 vector was prepared by di-
gesting the HPV16 E7 fragment from plasmid pcDNA3-E7 di-
gested with  Eco RI and  Xho I, and cloning the whole plasmid into 
the  Eco RI and  Xho I sites of the Lambda ZAP CMV vector. The 
packaging extracts (Gigapack  III Gold Packaging Extract; Strat-
agene) were used to package the recombinant   -phage vector with 
high efficiency  [14] . A wild   -ZAP phage was used as a negative 
control for further experiments.
 Purification of   -Phage Nanoparticles  
 The bacteriophages were amplified on  Escherichia coli strain 
XL1-Blue MRF’. The phages were purified and concentrated using 
standard microbiological techniques, as described before. Briefly, 
lysed cultures were cooled to room temperature. DNase I and 
RNase A (both Sigma Ltd., UK) were added to a final concentra-
tion of 1   g/ml and incubated for 30 min at room temperature. 
NaCl (1  M ) was added, and the flasks were left to stand on ice for 
1 h. Cell debris was removed by centrifugation at 11,000  g for 10 
min at 4° and the collected supernatants were pooled. Solid poly-
ethylene glycol (Sigma Ltd.) was added to a final concentration of 
10% (w/v), dissolved slowly at room temperature, and incubated 
at 4° for at least 1 h. The precipitated bacteriophage particles were 
recovered by centrifugation at 11,000  g for 10 min at 4° and the 
pellet was resuspended in phage buffer (SM; diluent and storage 
buffer used for routine manipulation of phage suspension). An 
equal volume of chloroform was added, and the culture was cen-
trifuged at 300  g for 15 min at 4°. The upper aqueous phase was 
then removed and the bacteriophages were pelleted by centrifuga-
tion at 26,000 rpm for 2 h at 4°. The bacteriophage pellet was re-
suspended in 1–2 ml of SM buffer at 4° overnight, pelleted once 
more and then resuspended in SM solution prior to storage or 
further manipulation  [9] .
 Mice and Cells 
 C57BL/6 mice (6–8 weeks old) were purchased from the Pas-
teur Institute (Karaj, Iran). The mice were housed for 1 week 
 before    the    experiment,    given    free    access   to   food   and   water, 
and maintained in a light/dark cycle with lights on from 6.00 to 
18.00 h. All experiments were done according to the guidelines 
for the care and use of laboratory animals by the ethical commis-
sion of the Tarbiat Modares University.
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 TC-1 (part of the Johns Hopkins Special Collection) was de-
rived from primary epithelial cells of C57BL/6 mice cotrans-
formed with HPV16 E6 and E7 and activated c-Ha- ras oncogene. 
The TC-1 cell line, which is HPV16 E7+, was used as a tumor 
model in an H-2b murine system. TC-1 and Chinese hamster ova-
ry (CHO) cell lines were grown in RPMI medium (RPMI 1640; 
Gibco-BRL, UK) supplemented with 10% (v/v) fetal calf serum 
(FCS), penicillin/streptomycin 50 U/ml, 2 m M glutamine, 1 m M 
sodium pyruvate, 2 m M nonessential amino acids and G418 0.4 
mg/ml at 37° with 5% CO 2 .
 In vitro Gene Delivery and Expression 
 Recombinant   -ZAP HPV16 E7 phages at an MOI of 10 6 were 
added to the CHO cell line. Transduction of target cells was en-
hanced using spinoculation or centrifugal enhancement after ad-
dition of phage particles  [15] . The cells were incubated in complete 
media for 48 h. Transfected CHO cells by wild-type   -phages were 
used as a negative control. To confirm the expression of recombi-
nant HPV E7 in the cell lines, Western blot analysis was per-
formed on the extracted total protein. Then, the cells were lysed 
in SDS loading buffer containing 1 m M dithiothreitol. Cellular 
proteins were separated on 15% polyacrylamide gels by SDS-
PAGE, blotted onto polyvinylidene difluoride membranes (Roche, 
Germany) and treated with the monoclonal HPV16 E7 mouse an-
tibody (Abcam, UK), followed by detection with goat anti-mouse 
secondary antibody conjugated to alkaline phosphatase (Sigma, 
St. Louis, Mo., USA) in secondary antibody solution. Color was 
developed by incubating the membrane in alkaline phosphate 
buffer containing tetramethylbenzidine substrate solution.
 Tumor Therapy Assay  
 For the in vivo therapeutic experiments, C57BL/6 mice (7 per 
group) were challenged by subcutaneous injection in the right 
flank with 2  ! 10 5 of TC-1 cells suspended in 100   l PBS. After 
1 week, the mice were immunized with 2  ! 10 12 particles (2  ! 
10 12 phages = 100   g DNA per mouse) of recombinant   -ZAP E7 
phage, wild   -ZAP phage (phage control) and PBS (negative con-
trol) via subcutaneous injection. The mice received 2 boosts with 
the same regimen 1 and 2 weeks later.
 The subcutaneous tumor volume was estimated according to 
Carlsson’s formula  [16] . Hence, the largest (a) and the smallest (b) 
superficial diameters of the tumor were measured twice a week 
and then the volume (V) of the tumor was calculated (V = a  ! b 
 ! b/2). Statistical analysis was performed using Student’s t test. 
All values were expressed as means  8 SD.
 Cytotoxic T Cell Assay 
 One week after the third immunization, the mice were sacri-
ficed and their splenocytes isolated. For each sample obtained 
from individual mice, single-cell suspensions of mononuclear 
cells (used as the effector cells) were cocultured in RPMI 1640 
medium with washed target cells (EL4) at various effector-to-tar-
get cell (E/T) ratios (25: 1, 50: 1 and 100: 1) and in 96-well flat-bot-
tom plates for 4 h in phenol red-free RPMI 1640 containing 3% 
FCS. For preparation of the target cells, EL4 cells were stimulated 
with 1   g/ml E7-specific H-2Db cytotoxic T cell (CTL) epitope 
(E7, amino acids 49–57) or 4  ! 10 5 TC-1 cells previously treated 
with mitomycin C (30   g/ml for 3 h) and then incubated for 4 h.
 After centrifugation, the supernatants (50   l/well) were trans-
ferred to the 96-well flat-bottom plates, and lyses of target cells 
were determined by measuring lactate dehydrogenase (LDH) re-
lease using a LDH cytotoxicity detection kit according to the pro-
cedures stated by the manufacturer (Takara Company, Shiga, Ja-
pan). Several controls were used for the cytotoxicity assay.
 The ‘high control’ was the total LDH released from the target 
cells, and all EL4 cells were lysed by medium containing 1% Tri-
ton X-100. The ‘low control’ was the natural release of LDH from 
the target cells, which was obtained by adding EL4 cells only to 
the assay medium. The ‘T cell control’ was used to measure the 
natural release of LDH from T cells and was obtained by adding 
the different ratios of T cells only to the assay medium. For all 
samples, including the controls, the assay was performed in trip-
licate.
 The LDH-mediated conversion of tetrazolium salt into a red 
formazan product was measured at 490 nm after incubation at 
room temperature for 30 min. The percentage of specific cytolysis 
was determined by the following formula  [17] : 
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 Lymphocyte Proliferation Assay 
 One week after the third immunization, a single-cell suspen-
sion of mononuclear cells obtained from immunized mice was 
used for the lymphocyte proliferation assay (LPA). Briefly, the 
suspension of isolated spleen cells was treated with lysis buffer 
(0.15  M NH 4 Cl; 1 m M KHCO 3 ; 0.1 m M Na 2 EDTA; pH 7.2) in order 
to clear red blood cells. In 96-well flat-bottom culture plates
(Nalge Nunc International, Denmark), 2  ! 10 5 cells per well were 
cultured. The preparations were cultured in RPMI 1640 supple-
mented with 10% FCS, 1%  L -glutamine, 1% HEPES, 0.1% 2-mer-
captoethanol and 0.1% penicillin/streptomycin, and incubated in 
the presence of 1   g/ml E7-specific H-2Db CTL epitope (E7, ami-
no acids 49–57) or 4  ! 10 5 TC-1 cells previously treated with mi-
tomycin C (30   g/ml for 3 h) per well at 37° in 5% CO 2 . 5   g/ml 
T cell mitogen phytohemagglutinin (Sigma Chemicals) was used 
as the positive control. After 3 days, 5   g/ml of MTT [3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma 
chemicals] was added to each well and incubated for 5 h at 37° in 
5% CO 2 . DMSO (100   l) was also added to dissolve formed forma-
zan crystals. Then, the plates were read at 540 nm, and the results 
expressed as a stimulation index (SI). The SI was determined as 
follows: optical density (OD) values of stimulated cells (Cs) minus 
relative cell numbers of unstimulated cells (Cu) divided by relative 
OD values of unstimulated cells:
 SI = (Cs – Cu)/Cu.
 All tests were performed in triplicate for each mouse.
 Granzyme B Release Assay 
 Seven days after the last immunization, the spleens were re-
moved (3 mice/day) and a single-cell suspension of mononuclear 
cells (effector cells) was prepared in RPMI 1640 (Gibco).
 The effector cells (100   l/well) were added to triplicate wells 
at specified concentrations followed by 5  ! 10 4 target EL4 cells/
E7-specific H-2Db CTL epitope (E7, amino acids 49–57) at differ-
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ent E/T ratios of 25: 1, 50: 1 and 100: 1 per well (100   l). After ef-
fector-target cell incubation for 6 h, the plate was centrifuged at 
1,000  g, the culture supernatant harvested and the granzyme B 
content measured by ELISA using a quantitative sandwich en-
zyme immunoassay technique (eBioscience Mouse Granzyme B 
ELISA Ready-SET) according to the manufacturer’s instruction. 
Briefly, Corning Costar 9018 96-well ELISA plates (Nalge Nunc 
International) were coated overnight at 4° with purified mouse 
anti-human GrB mAb (clone eB288/16G6; eBioscience Inc., San 
Diego, Calif., USA) in 0.1  M bicarbonate buffer (pH 9.6). After 
washing and blocking, the cell culture supernatants from wells for 
each group after 6 h of stimulation or GrB standards were added 
to the wells and then incubated at room temperature for 2 h. Bio-
tinylated mouse anti-human GrB (clone eBioLUEE) was added to 
the wells for 1 h, then washed extensively with washing buffer. 
Avidin-horseradish peroxidase was added for 30 min, then the 
ELISA plates were washed and GrB was detected after the addition 
of tetramethylbenzidine substrate solution. Absorbance was mea-
sured at 450 nm at various time points. The detection limit of the 
granzyme B ELISA system was 40 pg/ml.
 Cytokine Secretion Assay 
 One week after the third immunization, mononuclear cells 
from spleens of immunized mice at a concentration of 2  ! 10 6 
cells per well were incubated in 24-well plates (Nalge Nunc Inter-
national) for 2 days in a total volume of 1.5 ml of RPMI 1640 sup-
plemented with 10% FCS, 1%  L -glutamine, 1% HEPES, 0.1% 
2-mercaptoethanol and 0.1% penicillin/streptomycin, and pulsed 
with 1   g/ml E7-specific H-2Db CTL epitope at 37° in 5% CO 2 . 
The cell supernatants were collected and assayed for the presence 
of interferon (IFN)-  and interleukin (IL)-4, using commercially 
available sandwich-based ELISA kits (R&D Systems, Minneapo-
lis, Minn., USA) following the manufacturer’s instruction. All 
tests were performed in triplicate for each mouse.
 Statistical Analysis 
 To compare results between the different groups, a one-way 
ANOVA test was used. The statistical software SPSS version 11.0 
was utilized for statistical analyses. Differences were considered 
statistically significant when p  ! 0.05.
 Results 
 Construction of   -ZAP HPV16 E7 Phages 
 The presence of the E7 gene in packaged phages was 
confirmed by polymerase chain reaction using E7 prim-
ers ( fig. 1 a). Also, the plaque formation of the phages (agar 
on top) approved the subcloning and ligation steps  [14] 
( fig. 1 c). For protein analysis of   -ZAP E7 phages, West-
ern blot was performed on a CHO cell line which was 
transduced with recombinant   -ZAP HPV16 E7 phages 
at an MOI of 10 6 . 48 h after transduction, a signal corre-
sponding to the E7 protein (11 kDa) was detected by 
Western blotting, as shown in  figure 1 b.
 LDH Cytolytic Activity  
 The CTL response in immunized mice was examined 
in this study by the LDH release assay in 96-well plates. 
The mice were immunized 3 times, and the CTL activity 
was measured as described before (subsection Cytotoxic 
T Cell Assay). As shown in  figure 2 , lymphocytes in vac-
cinated mice with   -ZAP HPV16 E7 phages (39.4  8 1.3%) 
had a significantly increased specific cytolytic activity at 
an E/T ratio of 50: 1 when compared to that of wild   -ZAP 
phages (phage control; 22  8 2.07%) and PBS (negative 
control; 5.7  8 2.9%; p  ! 0.05). However, no statistically 
significant difference in cytolytic activity was found be-
tween the phage control and negative control groups at a 
50: 1 E/T ratio. The differences between all these groups 
at E/T ratios of 25: 1 or 100: 1 did not reach overall statisti-
cal significance. Based on these results, the CTL activities 
in mice immunized with   -ZAP HPV16 E7 phages were 
stronger than those in control ones.
 Lymphocyte Proliferation Response 
 Since lymphocyte proliferative responses are generally 
considered as a measure of cell-mediated immunity, HPV 
b
11 kDa E7
a
c
1 2 3
 Fig. 1.  a Polymerase chain reaction using 
E7 primers. The presence of E7 gene in   -
ZAP HPV16 E7 phages was confirmed by 
E7-specific primers.  b Western blot analy-
sis of CHO cells infected with   -ZAP 
HPV16 E7 phages. After overnight incuba-
tion, the cellular proteins were extracted 
and analyzed by SDS-PAGE and Western 
blotting.  c Plaque formation by recombi-
nant   -phages (agar on top). 
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E7 antigen-specific lymphocyte proliferation was evalu-
ated by MTT assay. As shown in  figure 3 , the mice im-
munized with   -ZAP HPV16 E7 phages induced a much 
better E7-specific proliferation response than the control 
groups, which received wild   -ZAP phages (phage con-
trol) and PBS (negative control; p  ! 0.05). These data in-
dicate the capability of   -ZAP phages as gene delivery 
vehicles to induce spleen cell proliferation as a marker of 
cellular immune response. 
 Induced Granzyme B Release Responses in Tumor 
C57BL/6 Mice 
 To determine whether bacteriophage-  particles could 
elicit antigen-specific cytolytic responses to a vectored 
insert, HPV16 E7 was inserted into the Lambda ZAP 
CMV vector, under transcriptional control of the CMV 
immediate-early promoter. One week after final immu-
nization, a single-cell suspension of splenocytes was in-
cubated with EL4 target cells/E7-specific H-2Db CTL 
epi tope. The cell supernatants were stored 6 h after incu-
bation to assay the granzyme B level by ELISA.
 Mice vaccinated with   -ZAP HPV16 E7 phages (205 
 8 20.4%) exhibited a significant increase in specific cy-
tolytic activity at an E/T ratio of 50: 1, as compared to that 
of wild   -ZAP phages (phage control; 42  8 12.8%) and 
PBS (negative control) ( fig. 4 ). The PBS value was lower 
than the limit of detection of the granzyme B ELISA sys-
tem (nondetectable). The   -ZAP HPV16 E7 phage group 
results have been statistically significant at p  ! 0.05 using 
the paired Student t test compared to the control groups.
 Secretion Levels of IFN-   
 To determine whether vaccination with the recombi-
nant   -ZAP phage vaccine could upregulate cytokine se-
cretion and increase specific immune responses, we mea-
sured IL-4 and IFN-  levels in the supernatants of mono-
nuclear cells from vaccinated mice restimulated in vitro 
with HPV E7 epitope. As shown in  figure 5 , splenocytes 
taken from immunized mice which received   -ZAP 
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 Fig. 2. CTL assays to demonstrate lymphocytes in mice vaccinat-
ed with different phage vaccines using quantitative measurement 
of LDH release. After mice were immunized with   -ZAP phages 
3 times, spleens were harvested as described in the Materials and 
Methods section. Data were collected from LDH results at various 
E/T ratios (25: 1, 50: 1, 100: 1) and expressed as percent cytotoxic-
ity  8 SD. The data shown here are from 3 independent experi-
ments in triplicate. 
0
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-ZAP E7
0.5
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Wild -ZAP PBS
 Fig. 3. Splenocyte proliferation levels after in vitro stimulation 
with HPV16 E7 epitope. C57BL/6 mice were challenged by subcu-
taneous injection of TC-1 cells. After 1 week, the mice were sub-
cutaneously immunized 3 times with   -ZAP HPV16 E7 phages, 
wild   -ZAP phages (phage control) and PBS (negative control). 
One week after final immunization, spleens of individual mice (3/
group) were removed and lymphocyte proliferation was evaluated 
by the MTT method. Formazan crystal formation after incuba-
tion with MTT was determined by solving the crystals in DMSO, 
and the OD was read at 540 nm. Bars: means. Whiskers: SEM. 
Lymphocyte proliferation in the   -ZAP HPV16 E7 phage group 
was significantly higher than in the control groups (p  ! 0.05).  
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HPV16 E7 phage vaccine produced higher levels of IFN-  
in comparison to the control groups, without any chang-
es in IL-4 levels. This result indicates that the   -ZAP 
HPV16 E7 phage vaccine regimen predominantly dis-
plays a Th1 cytokine profile.
  -ZAP E7 Phage Vaccine Protection against HPV16 
E7-Expressing Cells 
 To determine whether the observed increase in the 
number of E7-specific CD8+ T cells after vaccination 
with the recombinant   -ZAP E7 phage could be trans-
lated into a better E7-specific antitumor effect, we per-
formed an in vivo tumor treatment experiment via a pre-
viously characterized E7-expressing tumor model, TC-1 
 [18] . Mice were subcutaneously injected with 2  ! 10 5 
TC-1 cells per mouse into the right flank , and then im-
munized 3 times with recombinant   -ZAP E7 phage, wild 
  -ZAP phage and PBS in a 1-week interval. The tumors 
were measured twice a week once they became palpable. 
The controls consisted of unimmunized mice challenged 
with tumors. The tumor volume was monitored up to 30 
days after the tumor challenge. As shown in  figure 6 , 
mice treated with the recombinant   -ZAP E7 phage had 
significantly reduced tumor volumes when compared to 
mice treated with the wild   -ZAP phage and PBS (p  ! 
0.05). The results indicate that vaccination with the re-
combinant   -ZAP E7 phage induces a more efficiently 
therapeutic antitumor effect than vaccination in the con-
trol groups. 
 Discussion 
 Bacteriophage-based vectors have many desirable 
properties of both animal viral and nonviral systems 
without any significant drawbacks. Much like nonviral 
vectors, phage particles are simple genetic packages lack-
ing an intrinsic tropism for animal cells  [10] . However, a 
phage can be produced at high titers in bacterial cultures, 
potentially making the production simpler and more eco-
nomical than either nonviral or viral systems. Phage par-
ticles are also extremely stable under a variety of harsh 
conditions  [10, 19] . 
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 Fig. 4. Measured granzyme B in culture supernatants (stimulated 
spleen cells) by ELISA (quantitative sandwich enzyme immuno-
assay technique). One week after the last injection, mice were sac-
rificed and spleen cells pooled. Splenocytes were stimulated with 
EL4 target cells/E7-specific H-2Db CTL epitope. Samples were as-
sayed in triplicate. Bars: means of released granzyme B concentra-
tions. Whiskers: SD. The experiments were repeated twice more 
with similar results. The   -ZAP HPV16 E7 phage group results 
were statistically significant at p  ! 0.05 using the paired Student 
t test in comparison to the control groups. The PBS value was 
lower than the limit of detection of the granzyme B ELISA system. 
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 Fig. 5. Determination of the production of Th1 and Th2 cyto-
kines. Collected supernatants were screened for the presence of 
IFN-  and IL-4 to determine the phenotype (Th1 vs. Th2) of the 
immune responses. The concentration of the cytokines was deter-
mined by comparison to a standard curve of serially diluted pos-
itive control samples. Bars: means. Whiskers: SD. Each sample 
was examined in triplicate, and the results are representative of 2 
experiments (p  ! 0.05). 
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 In addition, phages have been experimentally admin-
istrated to animals and used in a safe manner for human 
applications which include the treatment of bacterial 
 infections and, more recently, immunization  [18, 20] . 
March et al.  [12] have shown the immunization by mul-
tiple injections of unmodified   -phage particles contain-
ing hepatitis B surface antigen resulting in a strong an-
tigen-specific humoral immune response in mice and 
rabbits. The authors speculated the response reflected an-
tibody-mediated opsonization of the phages during the 
subsequent immunizations. The results indicate that 
even unmodified nontargeted   -phage particles can me-
diate in vivo gene delivery, possibly due to their uptake by 
AP cells. Addressing the mechanism of phage-mediated 
gene transfer, and to test whether phagocytosis was re-
quired for this process, the findings by Lankes et al.  [21] 
showed phagocytosis to be responsible for a portion but 
not the majority of phage-mediated gene transfer. It is 
more likely that nonphagocytic mechanisms contribute 
to the uptake of phage particles and expression of phage-
encoded proteins. These include macropinocytosis, a 
process that is induced by many microbial pathogens 
 [22] . The major cell types capable of performing macropi-
nocytosis include dendritic cells and macrophages. Fol-
lowing uptake by AP cells, the DNA is released and the 
eukaryotic promoter directs a long-lasting expression of 
the vaccine antigen within the AP cells, maintaining a 
strong secondary response, which then induces the acti-
vated T and B cells to elicit an immune response to the 
antigen. This mechanism may explain enhanced im-
mune responses to vector-encoded mammalian antigens. 
 In order to detect the elimination of tumors by our   -
ZAP E7 phages, 4 immunogenicity tests – the LDH cyto-
toxicity test and IFN-  , LPA and granzyme B assays – 
were performed. The cytotoxicity test was carried out to 
test the immune response generated by the killing of the 
HPV16 oncogenic antigen-expressing cells (TC-1) by the 
  -ZAP E7 phage. The IFN-  assay was carried out to ex-
amine whether the immune response to TC-1 cells lay in 
a cell-mediated pathway or not. IFN-  is a cytokine in-
volved in cell-mediated immune response, especially for 
CTL and Th1 cells  [23] . Primed T cells usually respond 
quickly and strongly when they come into contact with 
antigens they have previously encountered. Generally, a 
large amount of IFN-  is produced when the primed T 
cells are in cell-mediated response. 
 To further evaluate cell-mediated immunity, the as-
says employing granzyme B were developed. Granzyme 
B is a lysosomal enzyme which mediates specific cyto-
toxic responses and has recently been implicated in anti-
viral defense  [24, 25] .
 The LDH cytotoxicity test and LPA showed abilities 
approximately 2.3- and 3-fold higher in the   -ZAP E7 
phage group than in the phage control group. Granzyme 
B and IFN-  demonstrated the best correlations with an-
titumor effect. Also, the tests showed approximately 4.8- 
and 3.5-fold higher values than the phage control group. 
The results seem to be logical as granzyme B is one of the 
major compounds of cytotoxic granules. To our knowl-
edge, this is the first time the secretion of granzyme B was 
studied in cervical cancer models  [26] . 
 Our findings indicate that secreted IFN-  and gran-
zyme B by activated CTL play a critical role in cellular 
immune responses, which is important for antitumor 
and  antiviral  effects.  Moreover,   granzyme   B   seems   to 
be an obvious candidate for the development of high-
throughput screening assays, and subsequently for the 
evaluation of cell-mediated immune responses to vac-
cines and immunotherapy  [26] . Relative antitumor ef-
fects induced by wild   -phages can be related to the natu-
ral immunostimulation of   -phages  [27] .
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 Fig. 6. Therapeutic vaccination against TC-1-induced tumors. 
Mice were inoculated with 2  ! 10 5 TC-1 tumor cells into the right 
flank and then treated with recombinant   -ZAP E7 phage, wild 
  -ZAP phage (phage control) and PBS (negative control) 7 days 
after inoculation. The mice were monitored for evidence of tumor 
growth by palpation and inspection twice a week. To determine 
the tumor volume, each individual tumor size was measured. Line 
and scatter plot graphs depicting the tumor volume (in mm3) are 
presented. The data presented are a representation of 2 indepen-
dent experiments. 
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 Here, we have attempted to characterize phage-medi-
ated gene transfer in vivo. This study provides first proof-
of-concept support for the notion that   -phage vectors 
may result in efficient cell-mediated immune responses 
and antitumor effects. It seems that phage nanoparticles 
may be taken up, at least in part, via nonphagocytic 
mechanisms, possibly including macropinocytosis. Our 
findings offer important insight into the mechanism of 
phage-mediated gene transfer and suggest possible mod-
ifications to improve phage-based vaccine delivery sys-
tems. 
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